Clinical and molecular markers of inherited von Willebrand disease type.3: Are deletions of the VWF gene associated with alloantibodies to VWF?

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 10, 2008, Pages 1726-1728

  Federici, Augusto B ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; CYTOSINE; DESMOPRESSIN; MOLECULAR MARKER; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; THYMINE; VON WILLEBRAND FACTOR;

ANAPHYLAXIS; ANTIBODY DETECTION; ANTIBODY TITER; AUTOSOMAL RECESSIVE INHERITANCE; CLINICAL FEATURE; CONTINUOUS INFUSION; DIAGNOSTIC ERROR; DISEASE SEVERITY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; GENE DELETION; GENE MUTATION; GENETIC ASSOCIATION; HOMOZYGOSITY; HUMAN; INCIDENCE; NOTE; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STOP CODON; SUBSTITUTION THERAPY; VON WILLEBRAND DISEASE; VON WILLEBRAND DISEASE TYPE 3;

BIOLOGICAL MARKERS; GENE DELETION; HUMANS; ISOANTIBODIES; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 52449098463     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03146.x     Document Type: Note

References (27)

1. Federici AB, Berntorp E, Lee CA. The 80th Anniversary of von Willebrand disease: History, management, research. Haemophilia 2006; 12: 563-72.
2. Federici AB, Mannucci PM. Management of inherited von Willebrand disease in 2007. Ann Med 2007; 39: 346-58.
3. Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR, et al. The Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease. A report of the Subcommittee on von Willebrand factor. J Thromb Haemost 2006; 4: 2103-14.
4. Eikenboom JCJ. Congenital von Willebrand disease type.3: Clinical manifestations, pathophysiology and molecular biology. Best Pract Res Clin Haematol 2001; 14: 365-79.
5. Silwer J. von Willebrand's disease in Sweden. Acta Paediatr Scand 1973; 238: 1-159.
6. Federici AB. Clinical diagnosis of von Willebrand disease. Haemophilia 2004; 10: 169-76.
7. Federici AB, Castaman G, Mannucci PM. Guidelines for the diagnosis and management of VWD in Italy. Haemophilia 2002; 8: 607-21.
8. Lak M, Peyvandi F, Mannucci PM. Clinical manifestations and complications of childbirth and replacement therapy in 348 Iranian patients with type 3 von Willebrand disease. Br J Haematol 2000; 111: 1223-9.
9. Mannucci PM, Bloom AL, Larrieu MJ, Nilsson IM, West RR. Atherosclerosis and von Willebrand factor I. Prevalence of severe von Willebrand's disease in western Europe and Israel. Br J Haematol 1984; 57: 163-9.
10. Iorio A, Oliovecchio E, Morfini M, Mannucci PM; Association of the Italian Hemophilia Centers Directors. Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis. Haemophilia 2008; 14: 444-53.
11. Mannucci PM, Federici AB. Antibodies to von Willebrand factor in von Willebrand disease. Adv Exp Med Biol 1995; 386: 87-92.
12. Shelton-Inloes BB, Chebab FF, Mannucci PM, Federici AB, Sadler JE. Gene deletion correlates with the development of alloantibodies in von Willebrand disease. J Clin Invest 1987; 79: 1459-65.
13. Ngo KY, Glotz VT, Koziol JA, Lynch DC, Gitschier J, Ranieri P, Ciavarella N, Ruggeri ZM, Zimmerman TS. Homozygous and heterozygous deletions of the von Willebrand factor gene in patients and carriers of severe von Willebrand disease. Proc Natl Acad Sci USA 1988; 85: 2753-7.
14. Peake IR, Liddell MB, Moodie P, Standen G, Mancuso DJ, Tuley EA, Westfield LA, Sorace JM, Sadler JE, Verwej CL. Severe type III von Willebrand's disease caused by deletion of exon 42 of the von Willebrand factor gene: Family studies that identify carriers of the condition and a compound heterozygous individual. Blood 1990; 75: 654-61.
15. Zhang ZP, Blombäck M, Egberg N, Falk G, Anvret M. Characterization of the von Willebrand factor gene (vWF) in von Willebrand disease type III patients from 24 families of Swedish and Finnish origin. Genomics 1994; 21: 188-93.
16. Schneppenheim R, Krey S, Bergmann F, Bock D, Budde U, Lange R, Mittler U, Meili E, Mertes G. Genetic heterogeneity of severe von Willebrand disease type III in the German population. Hum Genet 1994; 94: 640-52.
17. Baronciani L, Cozzi G, Canciani MT, Peyvandi F, Srivastava A, Federici AB, Mannucci PM. Molecular characterization of a multiethnic group of 21 patients with type 3 von Willebrand disease. Thromb Haemost 2000; 84: 536-40.
18. Baronciani L, Cozzi G, Canciani MT, Peyvandi F, Srivastava A, Federici AB, Mannucci PM. Molecular defects in type.3 von Willebrand disease: updated results from 40 multiethnic patients. Blood Cells Mol Dis 2003; 30: 264-70.
19. Schneppenheim R, Castaman G, Federici AB, Kreuz W, Marschalek R, Oldenburg J, Oyen F, Budde U. A common 253-kb deletion involving VWF and TMEM16B in German and Italian patients with severe von Willebrand disease type 3. J Thromb Haemost 2007; 5: 722-8.
20. Mannucci PM. Treatment of von Willebrand disease. N Engl J Med 2004; 351: 683-94.
21. Bergamaschini L, Mannucci PM, Federici AB, Coppola R, Guzzoni S, Agostoni A. Posttransfusion anaphylactic reaction in a patient with severe von Willebrand disease: Role of complement and alloantibodies to von Willebrand factor. J Lab Clin Med 1995; 125: 348-55.
22. Boyer-Neumann C, Dreyfus M, Wolf M, Veyradier A, Meyer D. Multi-therapeutic approach to manage delivery in an alloimmunized patient with type 3 von Willebrand disease. J Thromb Haemost 2003; 1: 190-2.
23. Ciavarella N, Schiavoni M, Valenzano E, Mangini F, Inchingolo F. Use of recombinant factor VIIa (Novoseven) in the treatment of two patients with type III von Willebrand disease and an inhibitor against von Willebrand factor. Haemostasis 1996; 26: 150-4.
24. Rossetti LC, Candela M, Bianco RP, de Tezanos Pinto M, Western A, Goodeve A, Larripa IB, De Brasi CD. Analysis of factor.VIII gene intron 1 inversion in Argentinian families with severe hemophilia A and review of the literature. Blood Coagul Fibrinolysis 2004; 15: 569-72.
25. Mohl A, Marschalek R, Masszi T, Nagy E, Obser T, Oyen F, Sallai K, BodòI, Schneppenheim R. An Alu-mediated novel large deletion is the most frequent cause of type 3 von Willebrand disease. J Thromb Haemost 2008; 6: 1729-35.
26. Rodeghiero F, Castaman G, Tosetto A, Battle J, Baudo F, Cappelletti A, Casana P, De Bosch N, Eikemboom JCJ, Federici AB, Lethagen S, Linari S, Srivastava A. The discriminant power of bleeding history for the diagnosis of von Willebrand disease type 1: An international, multicenter study. J Thromb Haemost 2005; 3: 2619-26.
27. Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB, Batlle J, Meyer D, Fressinaud E, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Budde U, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill F, et. al. A quantitative analysis of bleeding symptoms in type 1 of von Willebrand disease: Results from a multicenter European study (MCMDM-1VWD). J Thromb Haemost 2006; 4: 766-73.